Johnson & Johnson (FRA:JNJ)
Germany · Delayed Price · Currency is EUR | Market Cap | 380.60B |
| Revenue (ttm) | 77.35B |
| Net Income (ttm) | 19.34B |
| Shares Out | n/a |
| EPS (ttm) | 7.97 |
| PE Ratio | 19.68 |
| Forward PE | 16.97 |
| Dividend | 4.62 (3.00%) |
| Ex-Dividend Date | Aug 26, 2025 |
| Volume | 5,734 |
| Average Volume | 343 |
| Open | 153.14 |
| Previous Close | 153.16 |
| Day's Range | 153.14 - 154.10 |
| 52-Week Range | 129.00 - 161.60 |
| Beta | n/a |
| RSI | 62.18 |
| Earnings Date | Oct 14, 2025 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial numbers in USD Financial StatementsNews
U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor
TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six...
Best Dividend Aristocrats For October 2025
Dividend Aristocrats, tracked by NOBL, outperformed SPY in August but lagged year-to-date, with notable dispersion among individual stock returns. Dividend growth remains robust, with 55 of 69 Aristoc...
'I'm an optimist,' says Johnson & Johnson CEO on its R&D investment
CNBC's Jim Cramer sits down with Johnson & Johnson CEO Joaquin Duato to talk about the company's outlook, President Trump's 100% tariff on some pharmaceutical imports, cancer treatment innovation and ...
Watch Jim Cramer's interview with Johnson & Johnson CEO Joaquin Duato
CNBC's Jim Cramer sits down with Johnson & Johnson CEO Joaquin Duato to talk about the company's outlook, President Trump's 100% tariff on some pharmaceutical imports, cancer treatment innovation and ...
Johnson & Johnson (JNJ) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
Johnson & Johnson (NYSE:JNJ) Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 1:10 PM EDT Company Participants Tom Cavanaugh - Company Group Chairman for North America Innovative ...
The White House Kicks Tylenol Into Crisis Mode Again. Will Its PR Playbook Work This Time?
Robert Andrews would forever remember when his phone rang on Friday, September 30, 1982. He was assistant director for PR at Johnson & Johnson, whose pain reliever, Tylenol, was the […]
Johnson & Johnson (JNJ) Withdraws LINX System from Non-U.S. Markets
Johnson & Johnson (JNJ) Withdraws LINX System from Non-U.S. Markets
Johnson & Johnson (JNJ) Rebounds with 0.7% Increase in Early Trading
Johnson & Johnson (JNJ) Rebounds with 0.7% Increase in Early Trading
Johnson & Johnson (JNJ) Gains Following Stock Upgrade
Johnson & Johnson (JNJ) Gains Following Stock Upgrade
Guggenheim Upgrades Johnson & Johnson (JNJ) with Raised Price Target | JNJ Stock News
Guggenheim Upgrades Johnson & Johnson (JNJ) with Raised Price Target | JNJ Stock News
Johnson & Johnson, Boston Scientific to Headline MEDevice Boston 2025 Keynote Sessions
BOSTON, MA / ACCESS Newswire / September 23, 2025 / MEDevice Boston, the premier MedTech event connecting top OEMs (Original Equipment Manufacturers) with emerging suppliers and strategic partners, ha...
Stock Market Live September 23: OECD Predicts Faster Growth, But S&P 500 (VOO) Starts Flat
Live Updates Live Coverage Updates appear automatically as they are published. Johnson & Johnson Looks Healthy Sep 23, 2025 9:46 AM Live Speaking of Johnson & Johnson, Guggenheim analyst Vamil Divan u...
This Johnson & Johnson Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
Johnson & Johnson Ends Overseas Sales Of Acid Reflux Device Citing Market Factors
Johnson & Johnson (NYSE: JNJ) is reportedly halting international sales of its Linx Reflux Management System, a device used to treat chronic acid reflux . In a letter to doctors dated September 17, t...
J&J upgraded at Guggenheim on Innovative Medicine pipeline
Johnson & Johnson (JNJ) stock gains as Guggenheim upgrades the company to Buy highlighting its Innovative Medicine pipeline. Read more here.
Johnson & Johnson (JNJ) to Withdraw LINX Device from Markets Outside the U.S.
Johnson & Johnson (JNJ) to Withdraw LINX Device from Markets Outside the U.S.
Johnson & Johnson (JNJ) Withdraws Linx Reflux Management System Internationally
Johnson & Johnson (JNJ) Withdraws Linx Reflux Management System Internationally
Johnson & Johnson (JNJ) Receives Upgrade with Increased Price Target
Johnson & Johnson (JNJ) Receives Upgrade with Increased Price Target
J&J withdraws acid reflux device from non-US markets - report
Johnson & Johnson (JNJ) will withdraw its LINX Reflux Management System—a device used to treat acid reflux disease—from markets outside the U.S. from March,
J&J to withdraw acid reflux device from non-US markets, Bloomberg News reports
Johnson & Johnson will withdraw a device to treat acid reflux disease from markets outside the U.S., Bloomberg News reported on Tuesday, citing a company letter sent to doctors.
"No Credible Science": Tylenol Maker As Trump Links Painkiller With Autism
Kenvue, the Johnson and Johnson spinoff that sells Tylenol, issued a statement on Tuesday against US President Donald Trump linking the painkiller with autism, saying there is "no credible science" be...
These are the top 22 stocks pushing the S&P 500 into record territory — and it's not all Big Tech
DataTrek remains positive on U.S. large cap stocks, but expects more bearish commentary related to valuation in the days ahead
Johnson & Johnson's TREMFYA Gains FDA Nod For SC Induction In Ulcerative Colitis
(RTTNews) - Johnson & Johnson (JNJ) announced that the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of TREMFYA® (guselkumab) for adults with moderately to sever...
Johnson & Johnson (JNJ) Gains FDA Nod for New TREMFYA Treatment
Johnson & Johnson (JNJ) Gains FDA Nod for New TREMFYA Treatment
TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
TREMFYA ® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease TREMFYA ® achieved significant rates of...